Promising Pipeline and Strategic Partnerships Drive Buy Rating for Lineage Cell Therapeutics

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price target remains the same with $9.00.

Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Lineage Cell Therapeutics’ pipeline. The company recently announced its first-quarter 2025 financial results, which, despite a slight miss on EPS estimates, showed a strong cash position expected to support operations into the first quarter of 2027. A key factor in Pantginis’s positive outlook is the anticipated 3-year data update from the OpRegen program, which is being developed in collaboration with Roche/Genentech. This update is expected to demonstrate sustained anatomical and functional benefits in treating dry AMD, a degenerative condition, thus reinforcing the potential long-term efficacy of the treatment.
Additionally, Pantginis highlights the strategic advantage gained from Genentech’s involvement, particularly with the introduction of proprietary surgical delivery devices that enhance the OpRegen program’s competitive edge. The ongoing clinical progress and the backing from a major player like Roche position Lineage favorably in the AMD therapy space. Furthermore, the initiation of the Phase 2 DOSED study for OPC1 and the ongoing evaluation of the ANP1 program for hearing loss indicate a robust pipeline with multiple avenues for growth, supporting the Buy recommendation.

According to TipRanks, Pantginis is an analyst with an average return of -24.5% and a 23.60% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Actinium Pharmaceuticals, and Viking Therapeutics.